Literature DB >> 3666006

Correlation of histamine H1 receptor function and [3H]mepyramine binding in porcine tracheal tissue.

A G Driver1, S J Mustafa.   

Abstract

In order to validate the use of [3H]mepyramine as a radioligand to label airway histamine H1 receptors, the results of radioligand binding experiments using porcine tracheal tissue membranes were compared with the results of physiologic studies measuring histamine-induced trachealis muscle contraction. Close agreement was found between histamine-induced [3H]mepyramine binding inhibition and histamine concentration-contraction-response curves. Close agreement was also found between the KD of mepyramine-induced [3H]mepyramine binding inhibition and the K beta of mepyramine antagonism of muscle contractions stimulated by 10(-4) M histamine. [3H]Mepyramine binding was found to be rapid, reversible, saturable and stereospecific. Only H1 agonists and antagonists displayed potent [3H]mepyramine binding inhibition in competition binding studies. The results fulfill criteria for histamine H1 receptor identification by radioligand binding with [3H]mepyramine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3666006     DOI: 10.1016/0014-2999(87)90586-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis.

Authors:  Jeffrey Tessier; Candace Green; Diana Padgett; Wei Zhao; Lawrence Schwartz; Molly Hughes; Erik Hewlett
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

2.  Histamine H1-receptor-mediated inositol phospholipid hydrolysis in DDT1MF-2 cells: agonist and antagonist properties.

Authors:  T E White; J M Dickenson; S J Hill
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

3.  Augmentation of antigen receptor-mediated responses by histamine H1 receptor signaling.

Authors:  Y Banu; T Watanabe
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.